drugset
drugset / Trial / NCT02345265

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

NCT02345265 ↗

Phase 2 Active not recruiting 70 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2016-05-23
Primary completion
2022-07-07
Completion
2027-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule — Oral
Subject Olaparib Small molecule — Oral

Indications

fallopian tube endometrioid adenocarcinoma fallopian tube serous adenocarcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal serous adenocarcinoma